Sharekhan's research repor on Solara Active Pharma Sciences
Solara has delivered its best-ever quarterly performance, with the sales and PAT staging a sturdy growth of 13% and 96% yoy respectively. The company is witnessing improved demand traction across its segment and geographies and has revised upwards its FY2021 Revenue and EBITDA growth guidance to 30%+ and 40%+ respectively. It also expects 2HFY2021 to be stronger than 1HFY21. Strong growth prospects, better earnings visibility, healthy balance sheet, and improving return ratios would support multiple expansion.
Outlook
We retain our Buy recommendation on Solara Active Pharma Sciences (Solara) with a revised PT of Rs. 1,371.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.